MICA AI MEDICAL

MICA Artificial Intelligence Ltd. is an Israeli medical AI company developing advanced solutions for breast cancer detection, with a specific focus on women with dense breast tissue. Founded in 2020 and headquartered in Tel Aviv, MICA was established by a multidisciplinary team of experts in radiology, oncology, and artificial intelligence. The company’s flagship technology, M2C™, is an AI-based software that analyzes contrast-enhanced mammography–like information derived from standard mammography images, eliminating the need for contrast agents or additional imaging procedures. M2C™ is designed to support radiologists by improving cancer detection sensitivity while maintaining workflow efficiency and patient safety. MICA operates under a B2B model, partnering with hospitals, imaging centers, and healthcare providers. The company holds ISO 13485 certification and has received regulatory approvals in Israel and Argentina, with ongoing efforts toward U.S. FDA clearance. MICA collaborates with leading clinical institutions, including Sheba Medical Center, to validate its technology through clinical studies and real-world use.